throbber
Cornea 194 492496 2000
`
`2000 Lippincott Williams Wilkins Inc Philadelphia
`
`Tnterleukin-6 Levels in the Conjunctival Epithelium
`of Patients with Dry Eye Disease Treated with
`Cyclosporine Ophthalmic Emulsion
`
`Pflugfelder M.D Zhonghua Ji M.D
`Kathleen Turner D.V.M Stephen
`William Feuer M.S Michael Stern PhD and Brenda
`Reis PhD
`
`Purpose To evaluate interleukin-6 IL-6 levels in the conjuncti
`val epithelium of patients with moderate to severe dry eye disease
`ophthalmic emul
`before and after
`treatment with cyclosporin
`sion CsA or its vehicle Methods Conjunctival cytology speci
`6-month
`mens were obtained from subset of patients enrolled in
`trial of the efficacy and safety
`randomized double-masked
`clinical
`months of BID
`of topical CsA at baseline and after
`and
`13 0.1% cy
`emulsion
`treatment with 0.05% cyclosporine
`10 RNA was
`emulsion
`or vehicle
`closporine
`extracted and
`competitive reverse transcriptase polymerase chain
`reaction RT-PCR was used to evaluate the levels of mRNA en
`IL-6 and
`coding the inflammatory cytokine
`housekeeping
`gene
`G3PDH Levels of IL-6 and G3PDH were measured
`and com
`pared Results There was no change from baseline in the level of
`G3PDH after
`months
`in any group IL-6 normalized for
`or
`G3PDH IL-6/G3PDH ratio was not different
`from baseline at
`months
`but showed
`significant decrease from baseline
`in the
`group treated with 0.05% CsA
`months No
`0.048 at
`differences were noted and no correla
`significant between-group
`tion was observed between the change in IL-6/G3PDH and corneal
`staining Conclusions This preliminary small-cohort
`fluorescein
`study showed
`decrease in IL-6 in the conjunctival
`epithelium of
`moderate to severe dry eye patients treated with 0.05% CsA for
`months The observed decrease suggests that dry eye disease in
`volves immune-mediated inflammatory processes that may be de
`creased by treatment with topical ophthalmic cyclosporine
`Key Words ConjunctivaCyclosporin ADry eye disease
`
`Interleukin-6-Keratoconjunctivitis
`
`sicca
`
`Specific evidence of chronic immune activation of the conjunc
`tival epithelium in patients with dry eye suggests
`that cell-
`inflammatory processes may play an important role in
`mediated
`the pathogenesis of dry eye disease These immunopathologic
`of immunologic adhesion
`increased expression
`findings include
`i.e HLA class II and ICAM-1 antigens and inflam
`molecules
`
`Submitted September 13 1999 Revision received January
`cepted January 15 2000
`From the Bascom Palmer Eye Institute K.T S.C.P Z.J W.J.F De
`partment of Ophthalmology University of Miami School of Medicine
`Miami Florida and Allergan Inc MS B.L.R Irvine California
`U.S.A
`Supported by Allergan Inc 2525 Dupont Drive Irvine CA 927 13-9534
`U.S.A
`
`2000 Ac
`
`Address
`
`conespondence
`
`requests to S.C Pflugfelder M.D
`Bascom Palmer Eye Institute 900 NW 17th Street Miami FL 33136
`U.S.A
`
`and reprint
`
`492
`
`in these pa
`IL-6 IL-8 and TNF-ci
`IL-i
`matory cytokines
`tients.57 Among the inflammatory cytokines
`evaluated
`levels of
`interleukin-6 IL-6 showed the greatest elevation in eyes with dry
`eye disease when compared to normal eyes.6
`Further evidence that
`immune-mediated inflammatory processes
`are involved in the pathogenesis of dry eye disease comes from
`topical use of the immunomodulatory agent cyclospor
`reports that
`inc can improve the signs and symptoms of dry eye.8 However
`it has not been determined whether
`the use of topical cyclosporine
`can cause measurable decreases in any of the inflammatory mark
`ers that are associated with dry eye disease
`The purpose of this study was to evaluate the level of the in
`of patients with kera
`flammatory cytokine IL-6 in the conjunctiva
`
`toconjunctivitis sicca enrolled in
`
`ent concentrations
`
`and
`
`randomized trial of two differ
`ophthalmic emulsion CsA
`of cyclosporin
`castor oil emulsion vehicle IL-6 was chosen because pre
`the level of IL-6 mRNA is elevated
`vious studies have shown that
`epithelium of patients with Sjogrens syndrome
`in the conjunctival
`keratoconjunctivitis sicca.56 Furthermore the level of IL-6 mRNA
`was found to decrease in bronchoalveolar
`lavage cells obtained
`rejection who were treated
`
`from patients with acute lung transplant
`
`with aerosolized cyclosporine
`
`PATIENTS AND METHODS
`
`Patients
`
`Evaluation
`
`of the level of IL-6 mRNA in the conjunctiva was
`performed on conjunctival cytology specimens from subset of
`double-masked
`vehicle-
`patients enrolled in
`prospective
`trial of topical cyclosporine emul
`controlled multi-center clinical
`sion CsA for the treatment of dry eye disease.9 Adult patients of
`either sex were eligible for participation if
`they presented with
`diagnosis of moderate to severe dry eye disease as defined by the
`following criteria
`
`Schirmer test without anesthesia of
`
`mmJS minutes in at
`mmJS
`
`staining of
`
`least one eye If Schirmer test without anesthesia
`minutes then Schirmer with nasal stimulation had to be
`mm/S minutes in the same eye
`sum of corneal and interpalpebral conjunctival
`in the same eye where corneal staining was
`baseline Ocular Surface Disease Index OSDI score of 0.1
`with no more than three responses of not applicable and
`Facial Expression Scale
`on the Subjective
`score of
`The OSDI
`
`is
`
`questionnaire
`
`consisting of 12 questions each
`
`FAMY CARE - EXHIBIT 1014-0001
`
`

`

`CONJUNCTIVAL IL-6 IN DRY EYE DISEASE
`
`493
`
`Baseline
`
`Month
`
`Month
`
`Baseline
`
`Month
`
`Month
`
`433 PDH
`1O-
`
`IL6
`1O-
`
`G3PDH
`IO-
`
`JUt
`
`1ff5
`
`G3PDH
`1O
`
`IL-6
`1O
`
`G3PDH
`
`10-s
`
`IL-6
`o-
`
`G3PDH
`1O
`
`IL-6
`IO
`
`G3PDH
`1O
`
`IL-6
`1O
`
`aniol/gi
`
`amol/pi amol4Ll amot4tl amol/pi
`
`amoI4tI
`
`amollpl
`
`amol/pi amoL4fl amol/pi
`
`amoI4tl
`
`amol/jil
`
`21
`
`71
`
`Ethidium bromide-stained
`
`FIG
`Initial PCIR was performed using high and low concen
`agarose gel
`trations of mimics for G3PDH i0- and 10 attomole/pL and IL-6 i0- and 10
`attomole/pL The
`percentage of product G3PDH or IL-6 per total amplified product gene mimic in the lane is given
`the bottom amol
`attomole
`
`at
`
`rated from
`
`none of the time to
`
`evaluation of the impact of
`
`all of the time for the
`patients dry eye disease on his or her
`The overall score was calculated
`by
`vision-related functioning
`dividing the sum of the responses for all questions answered by the
`score and then multiplying by 100 Thus overall
`total possible
`no disability to 100
`scores ranged from
`
`complete disabil
`
`puncta within
`
`if
`
`punctal plugs during the study permanent occlusion of lacrimal
`months of the study or
`they were pregnant
`pregnancy Patients were also excluded if
`lactating or planning
`they appeared to have end stage lacrimal gland disease Schirmer
`nmil5 minutes or if
`their dry
`reading with nasal stimulation of
`eye disease was secondary to the destruction of conjunctival goblet
`cells or scarring Any patient who no longer met the criteria for
`moderate to severe dry eye as defined above after completing the
`run-in phase was excluded from enrollment
`2-week
`in the treat
`ment phase of the study
`Conjunctival epithelial samples were obtained at baseline at
`months and at months from four participating sites in the United
`States Informed consent was obtained from all patients before the
`study The study complied with the Tenets of the Declaration
`of
`by im
`Helsinki Conjunctival epithelial samples were obtained
`nitrocellulose membrane
`pression debridement with
`from the
`of the worse eye The worse eye
`temporal bulbar conjunctiva
`as the eye with the worse Schirmer tear
`was defined
`and the worse sum of corneal and interpalpe
`without anesthesia
`bral conjunctival staining If both eyes were comparable then the
`right eye was used The membranes were placed in Trizol RNA
`lysis buffer Life Technologies Rockville MD U.S.A and im
`mediately frozen at 80
`Samples were shipped in dry ice by
`commercial overnight delivery service to the central
`laboratory at
`the University of Miami School
`of Medicine Upon arrival
`samples were placed in 80
`the RNA was ex
`freezer until
`
`test value
`
`tracted
`
`Cornea Vol 19 No
`
`2000
`
`artificial
`
`visits if
`
`ity
`To be eligible for enrollment signs and symptoms of dry eye
`despite conventional management
`disease must have presented
`which may have included
`tear drops gels and ointments
`sympathomimetic agents parasympathomimetic agents and punc
`they were deemed
`tal occlusion Eligible patients were enrolled if
`capable of following the study protocol and were considered likely
`to complete the treatment period and to return for all scheduled
`they had normal
`lid position and closure and if
`they had
`retinopathy study vi
`best-corrected
`early treatment of diabetic
`sual acuity score of 0.7 logmar or better
`in each eye
`Patients were excluded from the study if
`they had used systemic
`or topical ophthalmic cyclosporine within 90 days before
`the
`study Other exclusion criteria included
`the presence or history of
`any systemic or ocular disorder or condition including
`ocular
`surgery trauma and disease that could possibly interfere with the
`interpretation of the study results current or recent use of topical
`that could affect
`ophthalmic or systemic medications
`dry eye
`condition known hypersensitivity to any component of the study
`lens wear during the
`or procedural medications required contact
`month or anticipated
`
`study recent within
`
`use of
`
`temporary
`
`FAMY CARE - EXHIBIT 1014-0002
`
`

`

`494
`
`TURNER ET AL
`
`Baseline
`
`Month
`
`Month
`
`O3PDH
`
`1L-6
`
`G3PDH
`
`1L6
`
`G3PDH
`
`TL-6
`
`cDNA- Marker
`
`FIG
`IRNA
`final gels for each patient
`Example of
`sample G3PDH primers were reacted with 1O at
`tomole/pL mimic and IL-6 with 1O attomole/pL
`mimic The upper band in each lane is the amplified
`product and the lower band is the amplified mimic
`are G3PDH and the G3PDH mimic
`Lanes
`and
`and
`are IL-6 and the IL-6 mimic Lanes
`and
`are month
`are baseline lanes
`is cDNA-PCIR
`and
`are month
`lanes
`lane
`reaction mixture without cDNA and lane
`is the
`DNA marker
`IX Boehringer
`IN
`Indianapolis
`U.S.A.
`
`lanes
`and
`
`CTG GAT TGC AGA GTT
`downstream primer sequence is
`AAG TTT
`constitutively expressed gene in all
`Cyclophilin is
`human cells that serves as the cyclosporine-binding protein.3 The
`PCR products were separated by
`.6% agarose gel electrophoresis
`and the intensity of the band was visually graded from no band
`strong cDNA samples that yielded
`bands were
`or
`used for competitive reverse transcriptase polymerase chath reaction
`RT-PCR analysis of IL-6 and G3PDH housekeeping gene levels
`cDNA samples that yielded
`bands were resynthesized
`or
`
`to
`
`Semiquantitative Analysis of mRNA Levels by
`Competitive RT-PCR
`The relative levels of RNA transcripts encoding the inflamma
`protein G3PDH were
`IL-6 or the housekeeping
`competitive PCR technique This technique was
`pL of sample cDNA to the PCR mixture
`performed by adding
`pL of primers specific
`described above containing
`for IL-6 or
`
`tory cytokine
`evaluated by
`
`using
`
`RNA Extraction and cDNA Synthesis
`RNA was extracted
`from the conjunctival
`epithelial samples
`previously reported protocol.5 Complementary DNA
`cDNA was synthesized with
`first strand cDNA synthesis kit
`pg of total RNA
`Boehringer Indianapolis IN U.S.A using
`Reverse transcriptase
`negative controls were performed for each
`RNA sample The efficiency of cDNA synthesis was assessed by
`evaluating the level of cyclophilin mRNA in each sample by poly
`merase chain reaction PCR amplification using 35 cycles We
`pL of cDNA to the PCR reaction mixture containing
`added
`pL
`pL deoxy-nucleotide triphosphates 10
`of lOx reaction buffer
`mmolJL deoxyadenosine
`triphosphate 10 mmolJL deoxycytidine
`triphosphate 10 mmol/L deoxyguanosine
`triphosphate and
`10
`mmolJL deoxythymidine triphosphate
`39.7 pL sterile water 0.3
`pL Taq DNA polymerase
`units/pL and
`pL of primers spe
`The upstream cyclophilin primer sequence
`cific for cyclophilin.2
`ATG GTT AAC CCC ACC GTG TTC GAC
`and
`the
`
`is
`
`TABLE
`
`Average percent of product
`
`G3PDH in lane
`
`Mimic 10
`
`attomole
`
`Mimic 10
`
`attomole
`
`lL-6 in lane
`
`Mimic 10
`
`attomole
`
`Mimic 10
`
`attomole
`
`Cyclosporine
`dose
`
`Vehicle
`
`Mo
`
`Mean
`
`47
`
`Std
`dev
`
`20
`
`Mean
`
`74
`
`Std
`dev
`
`19
`
`value
`
`0.002
`
`Mean
`
`21
`
`Std
`dev
`
`13
`
`18
`
`Mean
`
`41
`
`29
`
`Std
`dev
`
`27
`
`24
`
`value
`
`0.008
`
`0.005
`
`0.05%
`
`0.10%
`
`31
`
`32
`46
`
`27
`
`53
`37
`
`29
`
`24
`
`33
`
`22
`22
`
`22
`
`18
`20
`
`25
`
`17
`
`48
`
`70
`70
`
`46
`
`77
`57
`
`35
`
`40
`
`43
`
`28
`32
`
`43
`
`16
`31
`
`38
`
`22
`
`0.051
`
`0.001
`0.005
`
`0.026
`
`0.003
`0.012
`
`0.388
`
`0.025
`
`17
`
`34
`
`26
`
`34
`12
`
`16
`
`12
`
`26
`
`22
`
`27
`15
`
`19
`
`16
`
`61
`
`41
`
`53
`37
`
`31
`
`32
`
`10
`30
`
`34
`
`28
`17
`
`25
`
`26
`
`0.091
`0.005
`
`0.081
`
`0.004
`0.002
`
`0.003
`
`0.009
`
`Cornea Vol 19 No
`
`2000
`
`FAMY CARE - EXHIBIT 1014-0003
`
`

`

`CONJUNCTIVAL IL-6 IN DRY EYE DISEASE
`
`TABLE
`
`Change Th percent G3PDH from base/The
`
`Group
`
`Vehicle
`0.05% GsA
`0.10% GsA
`
`3-mo
`mean
`
`12
`15
`4.4
`
`SD
`
`31
`
`33
`
`27
`
`value
`
`0.4
`
`0.2
`
`0.6
`
`Range
`
`61 to 17
`72 to 28
`45 to 47
`
`6-mo
`mean
`
`13
`
`3.7
`
`12
`
`SD
`
`25
`
`27
`
`33
`
`value
`
`0.14
`
`0.6
`
`0.3
`
`495
`
`Range
`1521
`3864
`5535
`
`G3PDH.6 Both the IL-6 and G3PDH PCR reactions were run for
`35 cycles The primer sequences for IL-6 and G3PDH were chosen
`the PCR product was due to
`an intron to confirm that
`to span
`the am
`amplification of cDNA not genomic DNA The size of
`plified IL-6 cDNA product was 627 base pairs and the size of the
`amplified G3PDH cDNA product was 983 base pairs Each reac
`tion tube used to amplify the IL-6 cDNA was spiked with
`spe
`cifically designed mimic template Clontech Palo Alto CA
`U.S.A that contained DNA sequences that were complimentary
`to the IL-6 PCR primers These primer-specific sequences were
`nonspecific DNA fragment in
`and
`ends of
`ligated to the
`the v-erbB gene The mimic templates
`this case
`portion of
`compete with the IL-6-specific cDNA sequences in the conjunc
`tival epithelial specimens for the reaction primers and they have
`length in base pairs after PCR amplification than the
`different
`cytokine amplification product The added mimics also served as
`tube Two concentrations
`in each
`internal controls
`reaction
`of
`
`for
`
`mimic 10 and 106 attomole/pL
`were used for each sample
`PCR reactions
`for G3PDH were also spiked with two concentra
`tions 10 and i04 attomole/pL
`of mimic with G3PDH
`sequences PCR reactions
`IL-6 and G3PDH
`primer-specific
`month
`and month
`were performed on baseline month
`samples simultaneously for each subject The levels of PCR prod
`by 1.6% agarose gel electrophoresis Gels
`ucts were evaluated
`were stained with ethidium bromide 10 mg/mL and were photo
`Polaroid camera Cambridge MA U.S.A. Base
`graphed with
`for IL-6 and G3PDH
`PCR products
`line month
`and month
`and their mimics from each subject were run together on one
`Two final gels one for the lower and the other
`agarose gel Fig
`for the higher mimic concentration were run for each subject Fig
`The mimic concentration
`bands for IL-6
`yielding measurable
`and G3PDH that allowed
`between at
`comparisons
`or baseline to month
`points baseline to month
`was used for the final analysis
`month
`Photographs of each gel were scanned with
`
`least
`
`two time
`
`or month
`
`to
`
`Hewlett Packard
`
`expressed as
`
`ScanJet Palo Alto CA U.S.A. The integrated optical density of
`the IL-6 G3PDH and their mimic bands in the scanned images
`was measured Levels of IL-6 and G3PDH in each
`lane were
`in each lane e.g
`fraction of total amplified product
`IL-6/
`IL-6 mimic Levels of
`the percentage of IL-6
`G3PDH in each treatment group were compared over
`time to de
`the amount of G3PDH changed significantly with
`termine whether
`CsA treatment Levels of IL-6 were evaluated at each
`time point
`in relation to the level of G3PDH
`baseline month
`and month
`in each sample by dividing the percentage of IL-6 by the G3PHD
`normalized IL-6
`
`Statistical Analysis
`test was used to confirm that IL-6
`two-tailed paired Student
`and G3PDH as
`the product plus mimic total
`percentage of
`decreased with sample dilution for each group at each
`of G3PDH and IL-6 changes
`period Within group comparisons
`were performed with the two-tailed paired Student
`test Changes
`in the normalized IL-6 percentage from baseline to 3- and 6-month
`for each
`subject and between-group
`follow-up were calculated
`in the extent of change were examined with one-way
`analysis of variance
`
`differences
`
`follow-up
`
`RESULTS
`
`tive internal control
`
`Mimic as
`Competitive Internal Control
`Mimics were added to the PCR reactions to act both as
`for the PCR reaction
`and as
`template used for calculating
`the percentage of amplified cytokine
`or housekeeping protein To confirm the competitive nature of the
`mimic the percentage of IL-6 and G3PDH in each lane was com
`low mimic concentrations
`For each
`pared using high and
`ment group and time point the percentage of IL-6 and G3PDH
`of added mimic decreased Table
`increased as the concentration
`
`posi
`
`competitive
`
`treat
`
`TABLE
`
`Change Th %IL-6/%G3PDH ratio from base/The
`
`GsA 0.05%
`
`GsA 0.1%
`
`Vehicle
`
`Pvaluea
`
`Dayob
`
`1.1441.005
`
`n14
`
`Change from baseline
`Month
`0.036
`0.643
`n10
`0.862
`
`Within
`
`Month
`
`Within
`
`0.626
`1.025
`n13
`0.048
`
`1.401 1.198
`n12
`
`0.8460.663
`
`n10
`
`0.095
`
`0.384
`
`1.430
`n10
`0.839
`
`1.248
`
`n8
`
`0.413
`
`2.269
`
`5.524
`
`n7
`
`0.319
`
`0.460
`0.749
`n10
`0084d
`
`0.438
`
`0.221
`
`0.853
`
`values from one-way analysis of variance
`Among-group
`IL-6 to G3PDH
`bValues are mimic corrected ratios of
`value from paired-t-test
`Within-group
`Note CsA
`cyclosporine ophthalmic emulsion Values shown are
`mean
`decrease
`standard deviation
`negative value indicates
`from baseline
`
`Changes from Baseline
`There were no significant differences between G3PDH levels at
`This demon
`months
`in any treatment group Table
`or
`strates that the levels of the housekeeping protein G3PDH are not
`changed by CsA treatment
`The levels of IL-6 were then normalized to the G3PDH levels to
`in IL-6 mRNA levels At
`identify treatment-related
`changes
`months posttreatment
`significant decrease in the ratio of the
`percentage of IL-6 to G3PDH was observed in the group treated
`with 0.05% CsA but not
`in the vehicle or 0.10% CsA treatment
`The ratio of the percentage of IL-6 to G3PDH was
`groups Table
`not significantly different from baselthe at month
`in any treatment
`group There were no significant
`differences in the between-group
`ratios of the percentage of IL-6 to the percentage of G3PDH
`
`Cornea Vol 19 No
`
`2000
`
`FAMY CARE - EXHIBIT 1014-0004
`
`

`

`496
`
`TURNER ET AL
`
`DISCUSSION
`
`REFERENCES
`
`Stern ME Beuerman RW Fox RI Gao
`Mircheff AK Pflugfelder
`SC The pathophysiology of dry eye the interaction between the ocu
`lar surface and lacrimal glands Cornea 1998
`Pflugfelder SC Wilhelmus KR Osato AS Matoba AY Font RL The
`autoimmune nature of aqueous tear deficiency
`Ophthalmol 1986
`9315 137
`Munay SB Lee WR Senile atrophy of
`Damato BE Allan
`ease Br Ophthalmol 1984
`human lacrimal gland the contribution of chronic
`Gibson AAM Wilson
`Fonester JY Whaley
`WC Histology of the lacrimal gland in keratoconjunctivitis sicca Br
`Ophthalmol 1973
`conjunctival epithelium invest Ophthalmol Vis Sci 1994
`
`Williamson
`
`the
`
`inflammatory dis
`
`Dick
`
`Jones DT Monroy
`syndrome cytokine
`
`Ji
`
`Atherton SS Pflugfelder SC Sjögrens
`and Epstein-Ban viral gene expression within the
`
`Ji
`
`Afonso
`
`junctivitis
`
`Sall
`
`504
`Pflugfelder SC Jones
`Monroy
`Altered cytokine
`of patients with Sjögrens
`balance in the tear
`fluid and conjunctiva
`syndrome keratoconjunctivitis sicca Curr Eye Res 1999 1920111
`Piette JCH Conjunctival biopsy in Sjögrens
`Raphael
`Bellefgih
`syndrome correlations between histological and immunohistochemi
`features Histopathology 1988 191202
`cal
`Gunduz
`Ozdemir
`Topical cyclosporin treatment of keratocon
`sicca in secondary Sjogrens syndrome Acta Ophthalmol
`199472435442
`Stevenson OD Mundorf TK Reis BL CsA Phase
`Study
`Group Two multicenter
`randomized studies of the efficacy and safety
`of cyclosporine ophthalmic emulsion in moderate
`to severe dry eye
`disease Ophthalmology 2000 1076319
`Silverman MH
`10 Laibovitz RA Solch
`OConnell
`Andriano
`Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of
`keratoconjunctivitis sicca Cornea 1993 1231523
`11 lacono AT Smaldone GC Keenan RJ et al Dose-related
`reversal of
`acute lung rejection by aerosolized cyclosporine Am Respir Crit
`
`Care Med 1997
`human T-cell cyclophilin EMBO 1987
`Mihatsch MJ Foxwell
`13 Ryffel
`Woerly
`BM Distribution of
`the cyclosporin binding protein cyclophilin in
`human tissues immunology 199272399404
`14 Kunert KS Tisdale AS Stern ME Smith JA Gipson 1K Effect of
`cyclosporine ophthalmic emulsion on the number of
`inflammatory
`cells and goblet cells in conjunctival biopsies of patients with dry eye
`invest Ophthalmol Vis Sci 19994045771
`Saito
`Takeuchi
`Fujihara
`Conjunctival epithelium
`of HLA-DR in dry eye patients Ophthalmologica 1999
`
`12 Haendler
`
`Hofer-Warbinek
`
`Hofer
`
`Complementary DNA for
`
`Greiner
`
`Haendler
`
`abstract
`
`15 Tsubota
`
`expression
`2131619
`16 Fleiss JL The design and analysis of clinical experiments New York
`Wiley 1986
`17 Wood LC Stadler
`of cytokines
`expression
`
`Liou
`et al Banier disruption increases gene
`and the SSkD TNF receptor
`in murine skin
`
`Exp Dermatol 1997
`Feingold KR Thorfeldt CR Elias PM Optimization of
`18 Man MQ
`invest Dermatol 1996
`lipid mixtures for banier repair
`physiological
`1061096101
`
`The most important
`
`finding of the present study was that nor
`malized IL-6 levels significantly decreased from baseline after
`months of treatment with 0.05% CsA whereas the decreases seen
`treatment with either 0.1% CsA or vehicle were not statisti
`after
`cally significant The decrease in this inflammatory factor by cy
`closporine is consistent with the results of another study conducted
`taken from separate cohort of patients
`on conjunctival biopsies
`trial Kunert et al.4
`that participated
`in this multi-centered clinical
`significant decrease in the immune
`demonstrated
`there was
`that
`activation markers HLA-DR and CD1 la after
`months of treat
`ment with 0.05% CsA whereas these same markers increased in
`the vehicle group Other studies have demonstrated
`that
`increased
`levels of IL-6 and other
`inflammatory markers are associated
`with dry eye disease.575 For example
`study by Pflugfelder et
`al.6 used the same assay as the present study to demonstrate
`and TNF-1 RNA found
`the levels of IL-hi IL-6 IL-8 TNF-ci
`in the conjunctival epithelium of Sjogren syndrome patients were
`significantly greater than those found in control patients However
`the present study and
`study performed on this patient
`the other
`
`that
`
`population4 are the first
`
`to demonstrate that
`
`treatment
`
`for dry eye disease cyclosporin
`decrease several markers of inflammation
`
`topical ophthalmic
`can significantly
`
`In the present study no statistically significant between-group
`differences were seen in IL-6 levels Thus it
`is not possible to rule
`to the mean as the source of the IL-6 decrease.6
`out regression
`However
`more likely explanation may be
`large therapeutic
`effect observed in the vehicle group Disruption of epidermal bar
`inflammatory
`function results
`in increased levels of several
`cytokines including TNF-ci IL-i and IL-6 in the epidermis.7
`
`rier
`
`effect of the oil-in-water vehicle of this cyclosporine
`therapeutic
`emulsion might be expected
`as topical application of certain lipid
`mixtures can accelerate epidermal barrier recovery
`barrier insults in mice8
`very small amount of RNA was obtained from the samples
`for this study Consequently
`highly sensitive competi
`provided
`tive RT-PCR assay was used to evaluate the levels of IL-6 and
`constituently expressed gene G3PDH The assay was designed to
`these mRNAs in the
`determine
`the relative amount of each of
`competitive template mimic that was
`sample when compared to
`the PCR reaction
`added to
`each of
`tubes The validity of
`the levels of G3PDH were
`that
`approach is supported by the fact
`the study medication or the vehicle
`
`after defined
`
`this
`
`not affected by either
`In conclusion the findings of the present study demonstrate that
`topical CsA decreases the levels of IL-6 an inflammatory cytokine
`that is upregulated in the conjunctiva of patients suffering from dry
`eye disease
`
`Cornea Vol 19 No
`
`2000
`
`FAMY CARE - EXHIBIT 1014-0005
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket